-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DXc1/BCunfDMghEwYvcINvJfxc4h9rlMfwJVrf6oj0li8kmg+2v4ev5SijibGAC0 fU1NT3buBItKfB1PK97drg== 0001019687-03-000160.txt : 20030203 0001019687-03-000160.hdr.sgml : 20030203 20030203133338 ACCESSION NUMBER: 0001019687-03-000160 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030203 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BUCALO LOUIS R MD CENTRAL INDEX KEY: 0001180760 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: C/O TITAN PHARMACEUTICALS INC STREET 2: 400 OYSTER POINT BLVD CITY: S SAN FRANCISCO STATE: CA ZIP: 94080 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-49554 FILM NUMBER: 03536076 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 4152444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 SC 13G 1 bucalo_13g-123102.txt CUSIP NO. 88831 40 1 13G PAGE 1 OF 4 PAGES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(b) (Amendment No.__)* Titan Pharmaceuticals, Inc. --------------------------- (Name of Issuer) Common Stock, $.001 par value ----------------------------- (Title of Class of Securities) 888314 10 1 ----------- (CUSIP Number) December 31, 2002 ----------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] [ ] Rule 13d-1 (b) [ ] Rule 13d-1 (c) [X] Rule 13d-1 (d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 88831 40 1 13G Page 2 of 4 Pages - -------------------------------------------------------------------------------- 1. Name of Reporting Persons I.R.S. Identification Nos. of above persons (entities only) LOUIS R. BUCALO - -------------------------------------------------------------------------------- 2. Check the Appropriate Box If a Member of a Group (See Instructions) (a) [_] (b) [_] - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization UNITED STATES - -------------------------------------------------------------------------------- 5. Sole Voting Power NUMBER OF 1,788,902 SHARES ----------------------------------------------------------------- BENEFICIALLY 6. Shared Voting Power OWNED BY 0 EACH ----------------------------------------------------------------- REPORTING 7. Sole Dispositive Power PERSON 1,788,902 WITH: ----------------------------------------------------------------- 8. Shared Dispositive Power - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person - -------------------------------------------------------------------------------- 10. Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [_] - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 6.2% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) IN - -------------------------------------------------------------------------------- CUSIP No. 88831 40 1 13G Page 3 of 4 Pages Item 1(a). Name of Issuer: TITAN PHARMACEUTICALS, INC. Item 1(b). Address of Issuer's Principal Executive Offices: Item 2(a). Name of Person Filing: SEE ITEM 1 ON PAGE 2 Item 2(b). Address of Principal Business Office or if none, Residence: SEE ITEM 1(B) ABOVE Item 2(c). Citizenship: SEE ITEM 4 ON PAGE 2 Item 2(d). Title of Class of Securities: COMMON STOCK, $.001 PAR VALUE Item 2(e). CUSIP Number: 88831 40 1 Item 3. Not Applicable Item 4. Ownership: INCLUDES 1,438,671 SHARES UNDERLYING IMMEDIATELY EXERCISABLE OPTIONS (a) Amount Beneficially Owned: 1,788,902 (b) Percent of Class: 6.2 (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 1,788,902 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 1,788,902 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class: NOT APPLICABLE Item 6. Ownership of More than Five Percent on Behalf of Another Person: NOT APPLICABLE Item 7. Identification and Classification of Subsidiary Which Acquired the Securities: NOT APPLICABLE Item 8. Identification and Classification of Members of the Group: NOT APPLICABLE Item 9. Notice of Dissolution of Group: NOT APPLICABLE Item 10. Certification: NOT APPLICABLE CUSIP No. 88831 40 1 13G Page 4 of 4 Pages After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. JANUARY 30, 2003 By: /S/ LOUIS R. BUCALO, M.D. --------------------------- Louis R. Bucalo, M.D. -----END PRIVACY-ENHANCED MESSAGE-----